Mr. Jim Tananbaum Announces the Appointment of Dr. Molly as a Member of Foresite Capital Management
In a recent press release, Foresite Capital Management announced the appointment of Dr. Molly He, the former director of Illumina, as the firm’s venture partner. Dr. He has over one decade of experience in genomic research and pharmacology.
Dr. He becomes a member of Foresite Capital
According to Foresite Capital Management’s managing director, Mr. Jim Tananbaum, Dr. He is a prominent scientist with a keen interest in the next-generation sequencing. He also added that Foresite Capital Management is glad to have Dr. He as its venture partner. Based on her work background in drug development and genomics, she is bound to be a great asset to this company. Before joining Foresite Capital Management, Dr. He worked at Illumina where she oversaw protein reagent innovation and their subsequent improvements. She also used to work for Pacific Biosciences as she spent her time researching on molecular real-time sequencing chemistry. Dr. He is a graduate of Nankai University and holds a doctorate from the University of California. She has published various articles, and she is a proud owner of over 20 patents in protein biophysics and what Jim knows.
About Mr. Jim Tananbaum
Mr. Jim Tananbaum is a business executive and the founder of Foresite Capital Management, a San Francisco-based company. Mr. Tananbaum is a scholar, and he has studied in some of the finest colleges, such as Yale University, MIT, and Harvard University. Mr. Tananbaum holds a doctorate in medicine, which he acquired in 1989 from the revered Harvard Medical School. He also volunteers at Yale University as a member and president of the Advisory Board. Mr. Tananbaum also serves as the chief advisor for the Harvard-MIT HST Program and more information click here.
Mr. Tananbaum has worked for many firms, including GelTex, a business that manufactures non-systemic drugs. He is the founder of GelTex and managed this company for five years before joining Sierra Ventures in 1993. Mr. Tananbaum later helped establish Theravance (THRX) and served as its chief executive. He has served as the M.D. of Prospect Venture Partners for close to a decade. While working for this firm, he oversaw the PVP2 & PVP3 project. Currently, he serves as the principal of Foresite Capital Management, a company that manages healthcare investment fund and resume him.